patients making-pharmacy-first-work-need-further-innovation 
pharmaphorum
DECEMBER 18, 2022
We live in unprecedented times, where innovation in biosciences continues to accelerate. Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. Why current patient access solutions have come up short. Yet, the healthcare experience is antiquated.
Pharmaceutical Technology
JANUARY 20, 2023
However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. In a January business update , the company predicted it will make a minimum of $5 billion in new vaccine sales. In 2021, Moderna had a net income of $12.2
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ACRP blog
MARCH 21, 2024
The process of assessing clinical trial feasibility is in urgent need of improvement. Aimed at predicting whether a trial at a particular site will succeed, feasibility involves determining whether the site has the necessary patients, staff, technology, and other resources. Collaborative approaches are needed to improve this process.
pharmaphorum
FEBRUARY 25, 2022
This is a stark reminder that the industry still has further to go to convince patients it is working in their best interests. Pharma can only continue to grow their business models, and deliver faster for our growing population, if the public trusts the industry to deliver against their needs.
ACRP blog
JANUARY 10, 2024
Nadege Gunn: Need for study-agnostic funding for sites in diverse areas “The need for improved diversity of all kinds among trial participants will continue in 2024, with sponsor and CRO support critical to success,” said Nadege T. A promising approach is to recruit early-career staff from non-traditional backgrounds.
pharmaphorum
JULY 8, 2021
Spreading innovation in the NHS is as much about fostering collaboration and building relationships as it is about designing new interventions and launching new technologies. Our main focus is improving outcomes for patients by getting more rapid uptake of advances in life science technology and service reorganisation.”.
pharmaphorum
JANUARY 26, 2021
It’s swept aside several historic barriers to uptake, such as the healthcare professional and patient desire to physically meet, medical guidelines that focus on in-person diagnosis and reimbursement models that discourage remote consultation. As such, reps will need to be reskilled. As such, reps will need to be reskilled.
Expert insights. Personalized for you.
91 
Let's personalize your content